Reagents and Bioinformatics analysis

Tender description

Next Generation Sequencing (NGS) kits Lot 1: Award value estimated based on previous spend for 2023-24 financial year. This is a direct award to the existing supplier to save a significant amount of rework that would be required if the genetics lab was to switch to an alternative supplier. This will cover the spend for 2024-25 financial year. It is vital that the supply of these items is uninterrupted as any delay will impact on patient care including cancer surgery / treatments, stem cell transplants for patients with primary immune deficiencies and bone marrow failure and correct patient management to prevent irreversible brain damage in metabolic conditions.